EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Protagonist Therapeutics, Inc. (PTGX) had EBIT Margin of -985.17% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$4.71M |
|
$-39.34M |
|
-- |
|
$4.71M |
|
$51.13M |
|
$-46.42M |
|
$7.08M |
|
$-39.34M |
|
$-39.34M |
|
$-39.34M |
|
$-39.34M |
|
$-39.34M |
|
$-39.34M |
|
$-46.42M |
|
$-46.50M |
|
63.77M |
|
63.77M |
|
$-0.62 |
|
$-0.62 |
|
| Balance Sheet Financials | |
$586.42M |
|
$4.10M |
|
$115.26M |
|
$701.69M |
|
$44.94M |
|
-- |
|
$11.31M |
|
$56.25M |
|
$645.44M |
|
$645.44M |
|
$645.44M |
|
62.45M |
|
| Cash Flow Statement Financials | |
$94.65M |
|
$-98.15M |
|
$20.03M |
|
$97.47M |
|
$114.00M |
|
$16.53M |
|
$35.27M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
13.05 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-985.17% |
|
|
EBIT Margin |
-985.17% |
-- |
|
-834.87% |
|
-834.87% |
|
$93.20M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
8.08 |
|
11.14 |
|
-6.09% |
|
-6.09% |
|
-5.61% |
|
-6.09% |
|
$10.34 |
|
$1.46 |
|
$1.48 |
|